Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma

Cancer Immunology, Immunotherapy

Volumn 60, Issue 11, 2011, Pages 1509-1527

  Bograd, Adam J ^a   Suzuki, Kei ^a   Vertes, Eva ^a   Colovos, Christos ^a   Morales, Eduardo A ^a   Sadelain, Michel ^a   Adusumilli, Prasad S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Immune response to cancer; Immunomodulation; Immunotherapy; Mesothelioma; Tumor antigens

Indexed keywords

ADENOVIRUS VECTOR; BASILIXIMAB; BETA INTERFERON; CANCER VACCINE; CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CLODRONIC ACID; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GEMCITABINE; IMMUNOMODULATING AGENT; INTERLEUKIN 2; IPILIMUMAB; MESOTHELIN MONOCLONAL ANTIBODY VACCINE; MONOCYTE CHEMOTACTIC PROTEIN 1 ANTIBODY; PEMETREXED; PEPTIDE VACCINE; RECOMBINANT IMMUNOTOXIN SS1P ANTIBODY; TICILIMUMAB; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; WT1 PROTEIN VACCINE;

ABDOMINAL PAIN; ACTIVE IMMUNIZATION; ALLERGIC REACTION; ANAPHYLAXIS; ANASARCA; ANEMIA; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONGESTIVE HEART FAILURE; CYTOREDUCTIVE SURGERY; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; EDEMA; EMPYEMA; EOSINOPHILIA; FATIGUE; FLU LIKE SYNDROME; FLUSHING; GENE TRANSFER; HEART FAILURE; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; HYPOXIA; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFECTION; INJECTION SITE REACTION; LYMPHOCYTOPENIA; MACROPHAGE; MAST CELL; MELANOMA; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURISY; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY FAILURE; REVIEW; SEIZURE; SEPSIS; SERUM SICKNESS; SIDE EFFECT; SKIN DISEASE; SURVIVAL RATE; T CELL DEPLETION; TREATMENT INDICATION; TREATMENT RESPONSE; VASCULAR LEAK SYNDROME; VIRAL GENE DELIVERY SYSTEM; VOMITING; WEIGHT GAIN;

ANIMALS; HUMANS; IMMUNOTHERAPY; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 82355175864     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1103-6     Document Type: Review

References (131)

1. LM Krug HI Pass VW Rusch HL Kindler DJ Sugarbaker KE Rosenzweig R Flores JS Friedberg K Pisters M Monberg CK Obasaju NJ Vogelzang 2009 Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma J Clin Oncol 27 3007 3013 19364962 1:CAS:528:DC%2BD1MXoslyisLo%3D 10.1200/JCO.2008.20.3943
2. RM Flores LM Krug KE Rosenzweig E Venkatraman A Vincent R Heelan T Akhurst VW Rusch 2006 Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial J Thorac Oncol 1 289 295 17409872 10.1097/01243894-200605000-00004 (Pubitemid 47163979)
3. M Anraku KS Cunningham Z Yun M-S Tsao L Zhang S Keshavjee MR Johnston M de Perrot 2008 Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma J Thorac Cardiovasc Surg 135 823 829 18374762 10.1016/j.jtcvs.2007.10.026 (Pubitemid 351417931)
4. + tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection Cancer Immunol Immunother 59 1543 1549 20567822 1:CAS:528:DC%2BC3cXpt12lsLo%3D 10.1007/s00262-010-0881-6
5. JP Hegmans A Hemmes H Hammad L Boon HC Hoogsteden BN Lambrecht 2006 Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses Eur Respir J 27 1086 1095 16540497 1:CAS:528:DC%2BD28XlvF2hsb0%3D 10.1183/09031936.06.00135305 (Pubitemid 44914290)
6. JM Davis 1979 The histopathology and ultrastructure of pleural mesotheliomas produced in the rat by injections of crocidolite asbestos Br J Exp Pathol 60 642 652 540105 1:STN:280:DyaL3c7ltlyksw%3D%3D (Pubitemid 10219300)
7. PA Moalli JL MacDonald LA Goodglick AB Kane 1987 Acute injury and regeneration of the mesothelium in response to asbestos fibers Am J Pathol 128 426 445 2820232 1:CAS:528:DyaL2sXlvFaktrk%3D (Pubitemid 17139894)
8. ML Shin HI Firminger 1973 Acute and chronic effects of intraperitoneal injection of two types of asbestos in rats with a study of the histopathogenesis and ultrastructure of resulting mesotheliomas Am J Pathol 70 291 313 4689512 1:CAS:528:DyaE3sXptleitQ%3D%3D
9. JC Wagner G Berry 1969 Mesotheliomas in rats following inoculation with asbestos Br J Cancer 23 567 581 5360333 1:CAS:528:DyaE3cXivFKquw%3D%3D 10.1038/bjc.1969.70
10. BT Mossman A Churg 1998 Mechanisms in the pathogenesis of asbestosis and silicosis Am J Respir Crit Care Med 157 1666 1680 9603153 1:STN:280: DyaK1c3msVaqsA%3D%3D
11. -•) from alveolar macrophages exposed to asbestiform and nonfibrous particles Cancer Res 47 1681 1686 3028612 1:CAS:528: DyaL2sXitV2itbo%3D (Pubitemid 17044503)
12. C Dostert V Pétrilli R Van Bruggen C Steele BT Mossman J Tschopp 2008 Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica Science 320 674 677 18403674 1:CAS:528:DC%2BD1cXltFyis7c%3D 10.1126/science.1156995 (Pubitemid 351928351)
13. S Tanaka N Choe DR Hemenway S Zhu S Matalon E Kagan 1998 Asbestos inhalation induces reactive nitrogen species and nitrotyrosine formation in the lungs and pleura of the rat J Clin Investig 102 445 454 9664087 1:CAS:528:DyaK1cXkslOktLY%3D 10.1172/JCI3169 (Pubitemid 28335205)
14. N Choe S Tanaka W Xia DR Hemenway VL Roggli E Kagan 1997 Pleural macrophage recruitment and activation in asbestos-induced pleural injury Environ Health Perspect 105 Suppl 5 1257 1260 9400734 1:STN:280:DyaK1c%2FmtlGjsw%3D%3D
15. Y Wang SP Faux G Hallden DH Kirn CE Houghton NR Lemoine G Patrick 2004 Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite Int J Oncol 25 173 178 15202003 1:CAS:528:DC%2BD2cXlslylsr8%3D
16. K Donaldson F Murphy R Duffin C Poland 2010 Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma Part Fibre Toxicol 7 5 20307263 10.1186/1743-8977-7-5 1:CAS:528:DC%2BC3cXktVylt7o%3D
17. CA Poland R Duffin I Kinloch A Maynard WAH Wallace A Seaton V Stone S Brown W MacNee K Donaldson 2008 Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study Nat Nano 3 423 428 1:CAS:528:DC%2BD1cXotFehs7o%3D 10.1038/nnano.2008.111
18. A Takagi A Hirose T Nishimura N Fukumori A Ogata N Ohashi S Kitajima J Kanno 2008 Induction of mesothelioma in p53 +/- mouse by intraperitoneal application of multi-wall carbon nanotube J Toxicol Sci 33 105 116 18303189 1:CAS:528:DC%2BD1cXmtFKksLw%3D 10.2131/jts.33.105 (Pubitemid 351340768)
19. F Pages A Berger M Camus F Sanchez-Cabo A Costes R Molidor B Mlecnik A Kirilovsky M Nilsson D Damotte T Meatchi P Bruneval PH Cugnenc Z Trajanoski WH Fridman J Galon 2005 Effector memory T cells, early metastasis, and survival in colorectal cancer N Engl J Med 353 2654 2666 16371631 1:CAS:528: DC%2BD2MXhtlarsrrE 10.1056/NEJMoa051424 (Pubitemid 41817714)
20. L Zhang JR Conejo-Garcia D Katsaros PA Gimotty M Massobrio G Regnani A Makrigiannakis H Gray K Schlienger MN Liebman SC Rubin G Coukos 2003 Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 348 203 213 12529460 1:CAS:528:DC%2BD3sXksVehug%3D%3D 10.1056/NEJMoa020177 (Pubitemid 36077915)
21. Suzuki K, Kadota K, Sima CS, Sadelain M, Rusch VW, Travis WD, Adusumilli PS (2011) Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol Immunother, Jul 19 [Epub ahead of print]
22. RM Amini K Aaltonen H Nevanlinna R Carvalho L Salonen P Heikkila C Blomqvist 2007 Mast cells and eosinophils in invasive breast carcinoma BMC Cancer 7 165 17727696 10.1186/1471-2407-7-165 1:CAS:528:DC%2BD2sXhtFyrt73I (Pubitemid 350054212)
23. JK Chan A Magistris V Loizzi F Lin J Rutgers K Osann PJ DiSaia M Samoszuk 2005 Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer Gynecol Oncol 99 20 25 16055178 1:CAS:528:DC%2BD2MXhtVartrjO 10.1016/j.ygyno.2005.05.042 (Pubitemid 41354578)
24. T Ibaraki M Muramatsu S Takai D Jin H Maruyama T Orino T Katsumata M Miyazaki 2005 The relationship of tryptase- and chymase-positive mast cells to angiogenesis in stage I non-small cell lung cancer Eur J Cardiothorac Surg 28 617 621 16125954 10.1016/j.ejcts.2005.06.020 (Pubitemid 41345254)
25. AB Rajput DA Turbin MC Cheang DK Voduc S Leung KA Gelmon CB Gilks DG Huntsman 2008 Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4, 444 cases Breast Cancer Res Treat 107 249 257 17431762 10.1007/s10549-007-9546-3 (Pubitemid 350265695)
26. TJ Welsh RH Green D Richardson DA Waller KJ O'Byrne P Bradding 2005 Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer J Clin Oncol 23 8959 8967 16219934 10.1200/JCO.2005.01.4910 (Pubitemid 46211481)
27. H Cho HW Hur SW Kim SH Kim JH Kim YT Kim K Lee 2009 Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment Cancer Immunol Immunother 58 15 23 18414853 1:CAS:528:DC%2BD1cXht1yqs7bO 10.1007/s00262-008-0516-3
28. KM Sarraf E Belcher E Raevsky AG Nicholson P Goldstraw E Lim 2009 Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer J Thorac Cardiovasc Surg 137 425 428 19185164 10.1016/j.jtcvs.2008.05.046
29. SC Kao N Pavlakis R Harvie JL Vardy MJ Boyer N van Zandwijk SJ Clarke 2010 High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy Clin Cancer Res 16 5805 5813 20956618 1:CAS:528:DC%2BC3cXhsFamtLvN 10.1158/1078-0432.CCR-10-2245
30. BW Robinson C Robinson RA Lake 2001 Localised spontaneous regression in mesothelioma-possible immunological mechanism Lung Cancer 32 197 201 11325491 1:STN:280:DC%2BD3MvhtVWrtg%3D%3D 10.1016/S0169-5002(00)00217-8 (Pubitemid 32372611)
31. S Sakaguchi M Toda M Asano M Itoh SS Morse N Sakaguchi 1996 T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases J Autoimmun 9 211 220 8738965 1:STN:280:DyaK28zivVOlsg%3D%3D 10.1006/jaut.1996.0026 (Pubitemid 26163865)
32. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer Cancer Res 61 4766 4772 11406550 1:CAS:528:DC%2BD3MXks1GrtbY%3D (Pubitemid 32691889)
33. TJ Curiel G Coukos L Zou X Alvarez P Cheng P Mottram M Evdemon-Hogan JR Conejo-Garcia L Zhang M Burow Y Zhu S Wei I Kryczek B Daniel A Gordon L Myers A Lackner ML Disis KL Knutson L Chen W Zou 2004 Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 942 949 15322536 1:CAS:528:DC%2BD2cXntFSkt7g%3D 10.1038/nm1093 (Pubitemid 39273735)
34. + regulatory T cells in patients with gastrointestinal malignancies Cancer 98 1089 1099 12942579 10.1002/cncr.11618 (Pubitemid 37022112)
35. Q Gao S-J Qiu J Fan J Zhou X-Y Wang Y-S Xiao Y Xu Y-W Li Z-Y Tang 2007 Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection J Clin Oncol 25 2586 2593 17577038 10.1200/JCO.2006.09.4565 (Pubitemid 47041232)
36. G Rudge SP Barrett B Scott IR van Driel 2007 Infiltration of a mesothelioma by IFN-gamma-producing cells and tumor rejection after depletion of regulatory T cells J Immunol 178 4089 4096 17371963 1:CAS:528: DC%2BD2sXjt1WltLs%3D (Pubitemid 46492357)
37. DJ Needham JX Lee MW Beilharz 2006 Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy Biochem Biophys Res Commun 343 684 691 16563349 1:CAS:528:DC%2BD28XjtFGjs7s%3D 10.1016/j.bbrc.2006.03.018
38. M Anraku T Tagawa L Wu Z Yun S Keshavjee L Zhang MR Johnston M de Perrot 2010 Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma J Immunol 185 956 966 20548032 1:CAS:528:DC%2BC3cXotlylsrc%3D 10.4049/jimmunol.0900437
39. RG van der Most AJ Currie S Mahendran A Prosser A Darabi BW Robinson AK Nowak RA Lake 2009 Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy Cancer Immunol Immunother 58 1219 1228 19052741 10.1007/s00262-008-0628-9 1:CAS:528: DC%2BD1MXmsVGisrw%3D
40. RG van der Most AJ Currie AL Cleaver J Salmons AK Nowak S Mahendran I Larma A Prosser BW Robinson MJ Smyth AA Scalzo MA Degli-Esposti RA Lake 2009 Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth PLoS One 4 e6982 19746156 10.1371/journal.pone.0006982 1:CAS:528:DC%2BD1MXhtFKrsrnM
41. Wu L, Yun Z, Tagawa T, Rey-McIntyre K, Anraku M, de Perrot M (2011) Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model. J Thorac Oncol (Publish Ahead of Print)
42. + T-regulator cells Eur Respir J 34 162 175 19251786 1:CAS:528:DC%2BD1MXovFegsb4%3D 10.1183/09031936.00101008
43. A Sica P Larghi A Mancino L Rubino C Porta MG Totaro M Rimoldi SK Biswas P Allavena A Mantovani 2008 Macrophage polarization in tumour progression Semin Cancer Biol 18 349 355 18467122 1:CAS:528:DC%2BD1cXpsVGmsLo%3D 10.1016/j.semcancer.2008.03.004
44. L Bingle NJ Brown CE Lewis 2002 The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies J Pathol 196 254 265 11857487 1:STN:280:DC%2BD387it1eksQ%3D%3D 10.1002/path.1027 (Pubitemid 34189413)
45. MI Koukourakis A Giatromanolaki S Kakolyris KJ O'Byrne N Apostolikas J Skarlatos KC Gatter AL Harris 1998 Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival Br J Cancer 77 1696 1703 9635852 1:STN:280:DyaK1c3pslOktw%3D%3D 10.1038/bjc.1998.280 (Pubitemid 28230477)
46. IF Lissbrant P Stattin P Wikstrom JE Damber L Egevad A Bergh 2000 Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival Int J Oncol 17 445 451 10938382 1:STN:280: DC%2BD3M%2FjtVKnsQ%3D%3D
47. JW Pollard 2004 Tumour-educated macrophages promote tumour progression and metastasis Nat Rev Cancer 4 71 78 14708027 1:CAS:528:DC%2BD2cXos12qtA%3D%3D 10.1038/nrc1256 (Pubitemid 38082155)
48. BZ Qian JW Pollard 2010 Macrophage diversity enhances tumor progression and metastasis Cell 141 39 51 20371344 1:CAS:528:DC%2BC3cXlsVSgtLc%3D 10.1016/j.cell.2010.03.014
49. HB Salvesen LA Akslen 1999 Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas Int J Cancer 84 538 543 10502735 1:STN:280:DyaK1MvjsVWhsQ%3D%3D 10.1002/(SICI)1097-0215(19991022)84: 5<538::AID-IJC17>3.0.CO;2-B
50. N Volodko A Reiner M Rudas R Jakesz 1998 Tumour-associated macrophages in breast cancer and their prognostic correlations The Breast 7 99 105 10.1016/S0960-9776(98)90065-0 (Pubitemid 28230834)
51. V Izzi V Chiurchiu F D'Aquilio C Palumbo I Tresoldi A Modesti PM Baldini 2009 Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages Int J Oncol 34 543 550 19148491 1:CAS:528:DC%2BD1MXisVGisb8%3D
52. + T cells J Immunol 175 1483 1490 16034085 1:CAS:528:DC%2BD2MXmtlWjtrc%3D (Pubitemid 41023048)
53. + T regulatory cell activities in lung cancer Cancer Res 65 5211 5220 15958566 1:CAS:528: DC%2BD2MXltFemurc%3D 10.1158/0008-5472.CAN-05-0141 (Pubitemid 40827331)
54. NR Miselis ZJ Wu N Van Rooijen AB Kane 2008 Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma Mol Cancer Ther 7 788 799 18375821 1:CAS:528:DC%2BD1cXks1Gms7g%3D 10.1158/1535-7163.MCT-07-0579 (Pubitemid 351551032)
55. RM Steinman 2008 Dendritic cells in vivo: a key target for a new vaccine science Immunity 29 319 324 18799140 1:CAS:528:DC%2BD1cXhtF2jtLvI 10.1016/j.immuni.2008.08.001
56. RM Steinman J Banchereau 2007 Taking dendritic cells into medicine Nature 449 419 426 17898760 1:CAS:528:DC%2BD2sXhtV2is7%2FI 10.1038/nature06175 (Pubitemid 47509552)
57. JP Hegmans A Hemmes JG Aerts HC Hoogsteden BN Lambrecht 2005 Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells Am J Respir Crit Care Med 171 1168 1177 15764728 10.1164/rccm.200501-057OC (Pubitemid 40663731)
58. JD Veltman ME Lambers M van Nimwegen S de Jong RW Hendriks HC Hoogsteden JG Aerts JP Hegmans 2010 Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity J Biomed Biotechnol 2010 798467 20508851 10.1155/2010/798467 1:CAS:528:DC%2BC3cXmvVyktrk%3D
59. S Wada K Yoshimura EL Hipkiss TJ Harris H-R Yen MV Goldberg JF Grosso D Getnet AM Demarzo GJ Netto R Anders DM Pardoll CG Drake 2009 Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model Cancer Res 69 4309 4318 19435909 1:CAS:528:DC%2BD1MXlvFWltLc%3D 10.1158/0008-5472.CAN-08-4102
60. M Ho R Hassan J Zhang QC Wang M Onda T Bera I Pastan 2005 Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients Clin Cancer Res 11 3814 3820 15897581 1:CAS:528:DC%2BD2MXktFyrurc%3D 10.1158/1078-0432.CCR- 04-2304 (Pubitemid 40685601)
61. FM Johnston MC Tan BR Tan Jr MR Porembka EM Brunt DC Linehan PO Simon Jr S Plambeck-Suess TJ Eberlein KE Hellstrom I Hellstrom WG Hawkins P Goedegebuure 2009 Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer Clin Cancer Res 15 6511 6518 19843662 1:CAS:528:DC%2BD1MXhtlCjsrnJ 10.1158/1078-0432.CCR-09-0565
62. U Keilholz A Letsch A Busse AM Asemissen S Bauer IW Blau WK Hofmann L Uharek E Thiel C Scheibenbogen 2009 A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS Blood 113 6541 6548 19389880 1:CAS:528:DC%2BD1MXotlWrurk%3D 10.1182/blood-2009-02-202598
63. + T cells that recognize and kill human malignant mesothelioma tumor cells Clin Cancer Res 13 4547 4555 17671141 1:CAS:528:DC%2BD2sXotlGqu78%3D 10.1158/1078-0432.CCR-07-0708 (Pubitemid 47219725)
64. K Rezvani JM Brenchley DA Price Y Kilical E Gostick AK Sewell J Li S Mielke DC Douek AJ Barrett 2005 T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization Clin Cancer Res 11 8799 8807 16361568 1:CAS:528: DC%2BD2MXhtlWrsbnN 10.1158/1078-0432.CCR-05-1314 (Pubitemid 43005931)
65. R Hassan M Ho 2008 Mesothelin targeted cancer immunotherapy Eur J Cancer 44 46 53 17945478 1:CAS:528:DC%2BD2sXhsVOrurjN 10.1016/j.ejca.2007.08.028 (Pubitemid 350262830)
66. P Wheatley-Price B Yang D Patsios D Patel C Ma W Xu N Leighl R Feld BCJ Cho B O'Sullivan H Roberts MS Tsao M Tammemagi M Anraku Z Chen M de Perrot G Liu 2010 Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma J Clin Oncol 28 3316 3322 20498407 10.1200/JCO.2009.26.9944
67. BWS Robinson J Creaney R Lake A Nowak AW Musk N de Klerk P Winzell KE Hellstrom I Hellstrom 2003 Mesothelin-family proteins and diagnosis of mesothelioma Lancet 362 1612 1616 14630441 1:CAS:528:DC%2BD3sXovF2rsrk%3D 10.1016/S0140-6736(03)14794-0 (Pubitemid 37443528)
68. R Hassan J Williams-Gould SM Steinberg DJ Liewehr J Yokokawa KY Tsang RJ Surawski T Scott K Camphausen 2006 Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts Clin Cancer Res 12 4983 4988 16914588 1:CAS:528:DC%2BD28XotFKgtbY%3D 10.1158/1078-0432.CCR-06- 0441 (Pubitemid 44338587)
69. Y Zhang L Xiang R Hassan CH Paik JA Carrasquillo BS Jang N Le M Ho I Pastan 2006 Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice Clin Cancer Res 12 4695 4701 16899620 1:CAS:528: DC%2BD28XnvVGksLo%3D 10.1158/1078-0432.CCR-06-0346 (Pubitemid 44297823)
70. R Hassan W Ebel EL Routhier R Patel JB Kline J Zhang Q Chao S Jacob H Turchin L Gibbs MD Phillips S Mudali C Iacobuzio-Donahue EM Jaffee M Moreno I Pastan PM Sass NC Nicolaides L Grasso 2007 Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin Cancer Immun 7 20 18088084
71. M Sadelain I Rivière R Brentjens 2003 Targeting tumours with genetically enhanced T lymphocytes Nat Rev Cancer 3 35 45 12509765 1:CAS:528:DC%2BD38XpvVertbg%3D 10.1038/nrc971 (Pubitemid 37328885)
72. C Carpenito MC Milone R Hassan JC Simonet M Lakhal MM Suhoski A Varela-Rohena KM Haines DF Heitjan SM Albelda RG Carroll JL Riley I Pastan CH June 2009 Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains Proc Natl Acad Sci USA 106 3360 3365 19211796 1:CAS:528:DC%2BD1MXivF2jsbw%3D 10.1073/pnas. 0813101106
73. Moon EK, Carpenito C, Sun J, Wang L-CS, Kapoor V, Predina JD, Powell DJ, Riley J, June CH, Albelda SM (2011) Expression of a functional CCR2 receptor enhances tumor localization and eradication by human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 17(14):4719-4730
74. JP Huber J David Farrar 2011 Regulation of effector and memory T-cell functions by type I interferon Immunology 132 466 474 21320124 1:CAS:528:DC%2BC3MXktVKitL4%3D 10.1111/j.1365-2567.2011.03412.x
75. M Odaka DH Sterman R Wiewrodt Y Zhang M Kiefer KM Amin G-P Gao JM Wilson J Barsoum LR Kaiser SM Albelda 2001 Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-β Gene therapy is attributable to induction of systemic immunity Cancer Res 61 6201 6212 11507073 1:CAS:528:DC%2BD3MXmt12ktbk%3D (Pubitemid 32762558)
76. RJ Kruklitis S Singhal P Delong V Kapoor DH Sterman LR Kaiser SM Albelda 2004 Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma J Thorac Cardiovasc Surg 127 123 130 14752422 1:CAS:528:DC%2BD2cXhvVCjsrs%3D 10.1016/j.jtcvs.2003.08.034 (Pubitemid 38160475)
77. KA Smith 1988 Interleukin-2: inception, impact, and implications Science 240 1169 1176 3131876 1:CAS:528:DyaL1cXkt1Whtrs%3D 10.1126/science.3131876
78. DE Kern S Gillis M Okada CS Henney 1981 The role of interleukin-2 (IL-2) in the differentiation of cytotoxic T cells: the effect of monoclonal anti-IL-2 antibody and absorption with IL-2 dependent T cell lines J Immunol 127 1323 1328 6456304 1:CAS:528:DyaL3MXmtFyktLw%3D (Pubitemid 11020996)
79. + T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2 J Immunol 171 5051 5063 14607902 1:CAS:528:DC%2BD3sXoslyjt7o%3D (Pubitemid 37432786)
80. C Jackaman AM Lew Y Zhan JE Allan B Koloska PT Graham BW Robinson DJ Nelson 2008 Deliberately provoking local inflammation drives tumors to become their own protective vaccine site Int Immunol 20 1467 1479 18824504 1:CAS:528:DC%2BD1cXht12jtLrF 10.1093/intimm/dxn104
81. GJ van Mierlo AT den Boer JP Medema EI van der Voort MF Fransen R Offringa CJ Melief RE Toes 2002 CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity Proc Natl Acad Sci USA 99 5561 5566 11929985 10.1073/pnas.082107699 1:CAS:528:DC%2BD38XjtFKlt7o%3D (Pubitemid 34411588)
82. M Del Vecchio E Bajetta S Canova MT Lotze A Wesa G Parmiani A Anichini 2007 Interleukin-12: biological properties and clinical application Clin Cancer Res 13 4677 4685 17699845 1:CAS:528:DC%2BD2sXptVGmsbY%3D 10.1158/1078-0432.CCR- 07-0776 (Pubitemid 47294773)
83. MJ Brunda L Luistro RR Warrier RB Wright BR Hubbard M Murphy SF Wolf MK Gately 1993 Antitumor and antimetastatic activity of interleukin 12 against murine tumors J Exp Med 178 1223 1230 8104230 1:CAS:528:DyaK3sXlsFyjsL4%3D 10.1084/jem.178.4.1223 (Pubitemid 23277355)
84. JP Zou N Yamamoto T Fujii H Takenaka M Kobayashi SH Herrmann SF Wolf H Fujiwara T Hamaoka 1995 Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells Int Immunol 7 1135 1145 8527411 1:CAS:528:DyaK2MXmvVGlsbw%3D 10.1093/intimm/7.7.1135
85. I Caminschi E Venetsanakos CC Leong MJ Garlepp B Scott BW Robinson 1998 Interleukin-12 induces an effective antitumor response in malignant mesothelioma Am J Respir Cell Mol Biol 19 738 746 9806738 1:CAS:528:DyaK1cXnsFyju7Y%3D (Pubitemid 128353673)
86. I Caminschi E Venetsanakos CC Leong MJ Garlepp BW Robinson B Scott 1999 Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12 Am J Respir Cell Mol Biol 21 347 356 10460752 1:CAS:528:DyaK1MXmsVyjurw%3D (Pubitemid 129517189)
87. ZG Fridlender G Buchlis V Kapoor G Cheng J Sun S Singhal MC Crisanti LC Wang D Heitjan LA Snyder SM Albelda 2010 CCL2 blockade augments cancer immunotherapy Cancer Res 70 109 118 20028856 1:CAS:528:DC%2BC3cXkvFOr 10.1158/0008-5472.CAN-09-2326
88. S Kim G Buchlis ZG Fridlender J Sun V Kapoor G Cheng A Haas HK Cheung X Zhang M Corbley LR Kaiser L Ling SM Albelda 2008 Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy Cancer Res 68 10247 10256 19074893 1:CAS:528:DC%2BD1cXhsV2itL7L 10.1158/0008-5472.CAN-08-1494
89. + regulatory T cells J Exp Med 201 1061 1067 15809351 1:CAS:528: DC%2BD2MXjtFWlsrY%3D 10.1084/jem.20042276 (Pubitemid 40524674)
90. DA Thomas J Massagué 2005 TGF-[beta] directly targets cytotoxic T cell functions during tumor evasion of immune surveillance Cancer Cell 8 369 380 16286245 1:CAS:528:DC%2BD2MXht12gsbvK 10.1016/j.ccr.2005.10.012 (Pubitemid 41579832)
91. M Ahmadzadeh SA Rosenberg 2005 TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells J Immunol 174 5215 5223 15843517 1:CAS:528:DC%2BD2MXjsVertrs%3D (Pubitemid 40593159)
92. P Allavena A Sica C Garlanda A Mantovani 2008 The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance Immunol Rev 222 155 161 18364000 1:CAS:528:DC%2BD1cXlsFejtrc%3D 10.1111/j.1600-065X.2008.00607.x (Pubitemid 351430369)
93. ZG Fridlender J Sun S Kim V Kapoor G Cheng L Ling GS Worthen SM Albelda 2009 Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN Cancer Cell 16 183 194 19732719 1:CAS:528:DC%2BD1MXhsVChs7vN 10.1016/j.ccr.2009.06.017
94. PC Rodriguez AC Ochoa 2008 Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives Immunol Rev 222 180 191 18364002 1:CAS:528:DC%2BD1cXlsFejt78%3D 10.1111/j.1600-065X.2008.00608.x (Pubitemid 351430370)
95. AJ Currie RG van der Most SA Broomfield AC Prosser MG Tovey BW Robinson 2008 Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors J Immunol 180 1535 1544 18209049 1:CAS:528:DC%2BD1cXotlGltw%3D%3D
96. SA Broomfield RG van der Most AC Prosser S Mahendran MG Tovey MJ Smyth BW Robinson AJ Currie 2009 Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy J Immunol 182 5217 5224 19380767 1:CAS:528:DC%2BD1MXkslKju70%3D 10.4049/jimmunol.0803826
97. JG Egen MS Kuhns JP Allison 2002 CTLA-4: new insights into its biological function and use in tumor immunotherapy Nat Immunol 3 611 618 12087419 1:CAS:528:DC%2BD38Xksl2mtbs%3D 10.1038/ni0702-611 (Pubitemid 34752469)
98. DR Leach MF Krummel JP Allison 1996 Enhancement of antitumor immunity by CTLA-4 blockade Science 271 1734 1736 8596936 1:CAS:528:DyaK28XhvVWmsLk%3D 10.1126/science.271.5256.1734 (Pubitemid 26102823)
99. + T cell- and IL-2-dependent mechanism Immunity 11 483 493 10549630 1:CAS:528: DyaK1MXntFCnuro%3D 10.1016/S1074-7613(00)80123-5 (Pubitemid 29504203)
100. A van Elsas AA Hurwitz JP Allison 1999 Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation J Exp Med 190 355 366 10430624 10.1084/jem.190.3.355 (Pubitemid 29374833)
101. FS Hodi SJ O'Day DF McDermott RW Weber JA Sosman JB Haanen R Gonzalez C Robert D Schadendorf JC Hassel W Akerley AJ van den Eertwegh J Lutzky P Lorigan JM Vaubel GP Linette D Hogg CH Ottensmeier C Lebbe C Peschel I Quirt JI Clark JD Wolchok JS Weber J Tian MJ Yellin GM Nichol A Hoos WJ Urba 2010 Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 711 723 20525992 1:CAS:528:DC%2BC3cXhtVCrtrbN 10.1056/NEJMoa1003466
102. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr., Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526
103. PS Adusumilli DP Eisenberg BM Stiles S Chung M-K Chan VW Rusch Y Fong 2006 Intraoperative localization of lymph node metastases with a replication-competent herpes simplex virus J Thorac Cardiovasc Surg 132 1179.e1 1188.e1 10.1016/j.jtcvs.2006.07.005 (Pubitemid 44584955)
104. PS Adusumilli BM Stiles M-K Chan M Mullerad DP Eisenberg L Ben-Porat R Huq VW Rusch Y Fong 2006 Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses J Gene Med 8 603 615 16475242 1:CAS:528:DC%2BD28XmtFKnsro%3D 10.1002/jgm.877 (Pubitemid 43827253)
105. PS Adusumilli BM Stiles MK Chan DP Eisenberg Z Yu SF Stanziale R Huq RJ Wong VW Rusch Y Fong 2006 Real-time diagnostic imaging of tumors and metastases by use of a replication-competent herpes vector to facilitate minimally invasive oncological surgery FASEB J 20 726 728 16467372 1:CAS:528:DC%2BD28XjtlGqtr4%3D (Pubitemid 46671195)
106. DH Sterman A Recio RG Carroll CT Gillespie A Haas A Vachani V Kapoor J Sun R Hodinka JL Brown MJ Corbley M Parr M Ho I Pastan M Machuzak W Benedict XQ Zhang EM Lord LA Litzky DF Heitjan CH June LR Kaiser RH Vonderheide SM Albelda M Kanther 2007 A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses Clin Cancer Res 13 4456 4466 17671130 1:CAS:528:DC%2BD2sXotlGqtL8%3D 10.1158/1078-0432.CCR-07-0403 (Pubitemid 47219714)
107. DH Sterman A Recio AR Haas A Vachani SI Katz CT Gillespie G Cheng J Sun E Moon L Pereira X Wang DF Heitjan L Litzky CH June RH Vonderheide RG Carroll SM Albelda 2010 A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions Mol Ther 18 852 860 20068553 1:CAS:528:DC%2BC3cXksFGkug%3D%3D 10.1038/mt.2009.309
108. C Boutin E Nussbaum I Monnet J Bignon R Vanderschueren JC Guerin O Menard P Mignot G Dabouis JY Douillard 1994 Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma Cancer 74 2460 2467 7923001 1:STN:280:DyaK2M%2Fgslertg%3D%3D 10.1002/1097-0142(19941101)74: 9<2460::AID-CNCR2820740912>3.0.CO;2-N (Pubitemid 24320849)
109. SH Goey AM Eggermont CJ Punt R Slingerland JW Gratama R Oosterom R Oskam RL Bolhuis G Stoter 1995 Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study Br J Cancer 72 1283 1288 7577483 1:CAS:528:DyaK28XktVyquw%3D%3D 10.1038/bjc.1995.501
110. P Astoul D Picat-Joossen JR Viallat C Boutin 1998 Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study Cancer 83 2099 2104 9827714 1:CAS:528:DyaK1cXnvFShsL8%3D 10.1002/(SICI)1097-0142(19981115)83:10<2099:: AID-CNCR8>3.0.CO;2-3 (Pubitemid 28525391)
111. B Castagneto S Zai L Mutti A Lazzaro R Ridolfi E Piccolini A Ardizzoni L Fumagalli G Valsuani M Botta 2001 Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients Lung Cancer 31 303 310 11165411 1:STN:280:DC%2BD3M3ksVCntQ%3D%3D 10.1016/S0169-5002(00)00192-6 (Pubitemid 32107025)
112. M Lucchi A Chella F Melfi P Dini C Tibaldi G Fontanini A Mussi 2007
113. M Lucchi A Chella F Melfi P Dini M Ambrogi L Fino G Fontanini A Mussi 2007 A phase II study of intrapleural immuno-chemotherapy, pleurectomy/ decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma Eur J Cardiothorac Surg 31 529 533 17188885 10.1016/j.ejcts.2006.11.046 discussion 533-4 (Pubitemid 46329391)
114. S Bretti A Berruti L Dogliotti B Castagneto R Bertulli P Spadaro G Toscano P Astorre C Verusio R Lionetto P Bruzzi A Santoro 1998 Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian group on rare tumors Tumori 84 558 561 9862516 1:CAS:528:DyaK1MXms1Ogsw%3D%3D
115. CW Mulatero RT Penson D Papamichael NH Gower M Evans RM Rudd 2001 A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma Lung Cancer 31 67 72 11162868 1:STN:280: DC%2BD3M7ns1ykuw%3D%3D 10.1016/S0169-5002(00)00157-4 (Pubitemid 32012604)
116. G Ali L Boldrini M Lucchi A Picchi M Dell'Omodarme MC Prati A Mussi V Corsi G Fontanini 2009 Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact Br J Cancer 101 1869 1875 19935800 1:CAS:528:DC%2BD1MXhsVOhtLjN 10.1038/sj.bjc.6605438
117. G Ali L Boldrini M Lucchi A Mussi V Corsi G Fontanini 2009 Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor J Thorac Oncol 4 348 354 19155997 10.1097/JTO.0b013e3181989ddb
118. JP Hegmans JD Veltman ME Lambers IJ de Vries CG Figdor RW Hendriks HC Hoogsteden BN Lambrecht JG Aerts 2010 Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma Am J Respir Crit Care Med 181 1383 1390 20167848 1:CAS:528:DC%2BC3cXpsFSrsbk%3D 10.1164/rccm.200909-1465OC
119. MA Cheever JP Allison AS Ferris OJ Finn BM Hastings TT Hecht I Mellman SA Prindiville JL Viner LM Weiner LM Matrisian 2009 The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research Clin Cancer Res 15 5323 5337 19723653 10.1158/1078-0432.CCR-09-0737
120. SA Xue L Gao S Thomas DP Hart JZ Xue R Gillmore RH Voss E Morris HJ Stauss 2010 Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice Haematologica 95 126 134 19679884 10.3324/haematol.2009. 006486 1:CAS:528:DC%2BC3cXitlals7Y%3D
121. KM Amin LA Litzky WR Smythe AM Mooney JM Morris DJ Mews HI Pass C Kari U Rodeck FJ Rauscher III, et al. 1995 Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma Am J Pathol 146 344 356 7856747 1:STN:280:DyaK2M7mtVWgsQ%3D%3D
122. J Oates C Edwards 2000 HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma Histopathology 36 341 347 10759948 1:STN:280:DC%2BD3c3itlCgtA%3D%3D 10.1046/j.1365-2559.2000. 00770.x (Pubitemid 30198916)
123. LM Krug T Dao AB Brown P Maslak W Travis S Bekele T Korontsvit V Zakhaleva J Wolchok J Yuan H Li L Tyson DA Scheinberg 2010 WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer Cancer Immunol Immunother 59 1467 1479 20532500 1:CAS:528:DC%2BC3cXpt12lsLw%3D 10.1007/s00262-010-0871-8
124. R Hassan S Bullock A Premkumar RJ Kreitman H Kindler MC Willingham I Pastan 2007 Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. Infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers Clin Cancer Res 13 5144 5149 17785569 1:CAS:528:DC%2BD2sXpvFGqsrY%3D 10.1158/1078-0432.CCR-07-0869 (Pubitemid 47502082)
125. RJ Kreitman R Hassan DJ FitzGerald I Pastan 2009 Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P Clin Cancer Res 15 5274 5279 19671873 1:CAS:528:DC%2BD1MXpvFeitLY%3D 10.1158/1078-0432.CCR-09- 0062
126. R Hassan SJ Cohen M Phillips I Pastan E Sharon RJ Kelly C Schweizer S Weil D Laheru 2010 Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers Clin Cancer Res 16 6132 6138 21037025 1:CAS:528:DC%2BC3cXhsFOjtr%2FN 10.1158/1078-0432.CCR-10-2275
127. F Pages J Galon WH Fridman 2008 The essential role of the in situ immune reaction in human colorectal cancer J Leukoc Biol 84 981 987 18559950 1:CAS:528:DC%2BD1cXht1amsbvI 10.1189/jlb.1107773
128. F Pages A Kirilovsky B Mlecnik M Asslaber M Tosolini G Bindea C Lagorce P Wind F Marliot P Bruneval K Zatloukal Z Trajanoski A Berger WH Fridman J Galon 2009 In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer J Clin Oncol 27 5944 5951 19858404 1:CAS:528:DC%2BC3cXhtVWisL8%3D 10.1200/JCO.2008.19.6147
129. J Galon A Costes F Sanchez-Cabo A Kirilovsky B Mlecnik C Lagorce-Pages M Tosolini M Camus A Berger P Wind F Zinzindohoue P Bruneval PH Cugnenc Z Trajanoski WH Fridman F Pages 2006 Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 1960 1964 17008531 1:CAS:528:DC%2BD28XhtVSnsrnK 10.1126/science.1129139 (Pubitemid 44498003)
130. CG Clemente MC Mihm Jr R Bufalino S Zurrida P Collini N Cascinelli 1996 Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma Cancer 77 1303 1310 8608507 1:STN:280: DyaK287pslChtA%3D%3D 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID- CNCR12>3.0.CO;2-5 (Pubitemid 26102328)
131. Broomfield SA et al (2005) Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 65(17):7580-7584